Announcements Trials
Browse Landscape

Phase

Phase 2/3 1Phase 1/2 1

Status

Completed 2

Sponsor Class

OTHER 1FED 1

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 1

Conditions

Peripheral Nervous System Diseases 1Ototoxicity 1Breast Neoplasms 1

Interventions

Cyclophosphamide 909Carboplatin 787pembrolizumab 744Paclitaxel 742Cisplatin 709Bevacizumab 706Gemcitabine 619Docetaxel 579Rituximab 548Radiotherapy 541Dexamethasone 511Nivolumab 488Doxorubicin 444Fluorouracil 392Capecitabine 376Etoposide 358Pemetrexed 337Cytarabine 335Oxaliplatin 333Lenalidomide 328Prednisone 326fludarabine phosphate 316Erlotinib Hydrochloride 314Trastuzumab 300Leucovorin 299fludarabine 296Vincristine 287Filgrastim 284Bortezomib 284Cetuximab 276

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Has results × Thioctic Acid × Clear all
NCT01313117 2014-10-02

Alpha-lipoic Acid in Patients at Risk for Paclitaxel Induced Neuropathy

Northwestern University

Phase 1/2 Completed
9 enrolled 7 charts
Breast

Breast Neoplasms, Peripheral Nervous System Diseases

NCT00477607 2014-03-07

Alpha-Lipoic Acid in Preventing Hearing Loss in Cancer Patients Undergoing Treatment With Cisplatin

VA Office of Research and Development

Phase 2/3 Completed
39 enrolled 11 charts

Ototoxicity

Data powered by HemOnc (CC BY 4.0) Colophon âš¡